Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Liquidia Corp (LQDA)
A forensic read on Liquidia Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
8.1
Distress distance
Clean
Earnings quality
4
Forensic signals
43.2
P / E (ttm)
-154.0%
ROE
$6.0B
Market cap
1031.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Liquidia Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 8.1, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-2731.3%
FY2025
Return on invested capital.Return on invested capital is -2731.3% in the latest fiscal year and slipping across FY2023–FY2025 from -360.0%. After-tax operating profit was ($58M) in FY2023 and ($41M) in FY2025, with operating income at -419.6% of revenue in FY2023, -866.6% in FY2024 and -32.5% in FY2025. The capital base behind it came down -91% across FY2023–FY2025, from $16M to $1M, so this is a return struck on a smaller base rather than a record of money put to work.
+15.1%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +32% over the last 2 years to FY2025 (+15.1%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~15.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~24%.
125d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 71 to 125 days FY2024→FY2025 (receivables +1889% vs revenue +1031%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 85 → 71 → 125 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.
19% of rev
FY2025
Key fundamentals
Latest Revenue$158.3M
Revenue Growth YoY+1031.2%
Revenue CAGR (2yr)+200.7%
Net Margin-43.5%
Free Cash Flow-$40.0M
Return on Equity-154.0%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Liquidia Corp's actual 10-K/10-Q/8-K filings?
Stock-based compensation ran 19% of revenue in FY2025 — about $0.34 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 15.2% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.